Page last updated: 2024-08-16

rivastigmine and Cognition Disorders

rivastigmine has been researched along with Cognition Disorders in 99 studies

Research

Studies (99)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (5.05)	18.2507
2000's	68 (68.69)	29.6817
2010's	25 (25.25)	24.3611
2020's	1 (1.01)	2.80

Authors

Authors	Studies
Elango, DS; Espay, AJ; Gomez-Mancilla, B; Mahajan, A; Marsili, L; Masellis, M; Pathan, R; Pezous, N; Pilotto, A; Sturchio, A	1
Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D	1
Arizaga, RL; Demey, I; Rojas, G	1
Budni, J; de Oliveira, MB; Deroza, PF; Fraga, DB; Heylmann, AS; Julião, RF; Luca, RD; Pacheco, FD; Quevedo, J; Volpato, AM; Zugno, AI	1
Arnoudse, NM; De La Garza, R; Kalechstein, AD; Mahoney, JJ; Shapiro, BA; Verrico, CD	1
Ben-Shlomo, Y; Close, JC; Henderson, EJ; Lawrence, AD; Lord, SR; Whone, A	1
Bolle, N; Bucik, V; Kobal, J; Sešok, S; Vodušek, DB	1
Bartha, R; Borrie, MJ; Penner, J; Wells, JL; Woolmore-Goodwin, SM	1
Birks, JS; Grimley Evans, J	1
Ferris, S; Isaacson, RS; Meng, X; Velting, DM	1
Agrawal, N; Dougall, D; Poole, N	1
Callegari, F; He, L; Hong, Z; Shang, L; Strohmaier, C; Wang, N; Wang, YP; Weisskopf, M; Zhang, ZX; Zhao, G; Zhao, ZX	1
Filarowska, J; Gawel, K; Gibula-Bruzda, E; Jenda, M; Kotlinska, JH; Labuz, K; Marszalek-Grabska, M; Silberring, J	1
Brenner, T; Faranesh, N; Irony-Tur-Sinai, M; Lavi, E; Lavon, I; Nizri, E; Weinstock, M	1
Candela, A; Cauli, O; Compañ, A; Felipo, V; García-Ayllón, MS; Jover, R; Martínez, S; Pérez-Mateo, M; Rodrigo, R; Sáez-Valero, J; Silveyra, MX	1
Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakizade, N; Zanjani, HA	1
Deiana, S; Harrington, CR; Riedel, G; Wischik, CM	1
Ballard, C; Emre, M; He, Y; Lane, R; Leverenz, JB; Morris, C	1
Borovikova, VN; Driagina, NV; Kondrat'ev, SA; Kondrat'eva, EA; Voronenko, VA	1
Arciniegas, DB; Gunay, I; Harvey, PD; Katz, DI; Koumaras, B; Meng, X; Potkin, SG; Reyes, PF; Silver, JM	1
Birks, J; Grimley Evans, J; Holt, FE; Iakovidou, V; Tsolaki, M	1
Alin, J; Helenius, H; Tenovuo, O	1
Adler, CH; Almaraz, AC; Caselli, RJ; Caviness, JN; Demaerschalk, BM; Driver-Dunckley, ED; Wellik, KE; Wingerchuk, DM; Woodruff, BK	1
Darreh-Shori, T; Ferris, S; Lane, R; Nordberg, A; Soininen, H	1
Farlow, M; Feldman, HH; Ferris, S; Lane, R; Sfikas, N; Winblad, B	1
Dautzenberg, PL; Nijboer, H	1
Chen, HZ; Cui, YY; Li, J; Shao, BY; Song, MK; Wang, H; Xia, Z; Xu, ZP; Zhang, WW	1
Bakar, M; Gumustas, O; Parlayan, E; Yulug, B	1
Chang, HM; Chen, CP; Chen, I; Corrales, MP; Effendy, S; Hia, SB; Lee, JM; Narasimhalu, K; Sim, CH; Tan, EK; Wong, MC; Xue, HL	1
Berg, D; Di Santo, A; Gaenslen, A; Gasser, T; Godau, J; Liepelt, I; Schweitzer, KJ	1
Chan, A; Fan, D; Leung, G; Mok, V; Poon, WS; Wong, A; Wong, GK; Wong, R	1
Aarsland, D; Brønnick, KS; Meng, X; Olin, JT; Schmitt, FA; Tekin, S	1
Berrut, G; Bourdeix, I; Carcaillon, L; Dartigues, JF; Gillette, S; Pere, JJ; Sellal, F	1
Alkam, T; Furukawa-Hibi, Y; Greig, NH; Matsuyama, A; Mizoguchi, H; Moussaoui, S; Nagai, T; Nitta, A; Suzuki, K; Yamada, K; Yu, QS	1
Hämäläinen, H; Hämäläinen, P; Huolman, S; Laine, T; Parkkola, R; Ruutiainen, J; Vorobyev, V	1
Meng, X; Somogyi, M; Weintraub, D	1
Banerjee, BD; Jain, S; Khurana, S; Mediratta, PK; Sharma, KK	1
Gray, SL; McDermott, CL	1
Fox, C; Maidment, I; McShane, R; Rolinski, M	1
Chen, CH; Chen, SH; Chou, MC; Liu, CK; Wu, SJ; Yang, YH	1
Baier, M; Hofmann, W; Mäurer, M; Meergans, M; Ortler, S; Scherer, P; Tracik, F	1
Barberger-Gateau, P; Bourdeix, I; Dartigues, JF; Goulley, F; Péré, JJ	1
Gandelman-Marton, R; Klein, C; Rabey, JM; Werber, EA	1
Doody, RS	1
Adler, G; Brassen, S; Chwalek, K; Dieter, B; Teufel, M	1
Erkinjuntti, T; Feldman, H; Gauthier, S; Rockwood, K; Román, G	1
Darreh-Shori, T; Flores-Flores, C; Guan, ZZ; Hellström-Lindahl, E; Nordberg, A; Soreq, H	1
Almkvist, O; Darreh-Shori, T; Nordberg, A; Spiegel, R; Stefanova, E	1
Feldman, H; Ferris, S; Hermann, N; Lane, R; Mancione, L; Mesenbrink, P; Scarpini, E; Scheltens, P; Tekin, S	1
Aimonovitch, M; Buchanan, T; Chez, MG; Mrazek, S; Tremb, RJ	1
Antonello, RM; Bava, A; Cazzato, G; Griggio, S; Moretti, R; Torre, P; Ukmar, M	1
Kaufer, DI	1
Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E	1
de Tommaso, M; Difruscolo, O; Sciruicchio, V; Specchio, LM; Specchio, N	1
Aupperle, PM; Chen, M; Koumaras, B; Mirski, D; Rabinowicz, A	1
García-Borreguero, D; Serrano, C	1
Charles, HC; Farlow, MR; He, Y; Lane, R; Tekin, S; Xu, J	1
Tenovuo, O	1
Simard, M; van Reekum, R	1
Cruz-Jentoft, AJ; del Ser, T; Fernández-Bullido, Y; Frank, A; Galiano, M; García de la Rocha, ML; González-Salvador, MT; Muñiz, R; Navarro, E; Olazarán, J; Peña-Casanova, J; Reisberg, B; Serra, JA; Serrano, P; Sevilla, C	1
Ballard, C; Bannister, C; Douglas, S; Elvish, R; Everratt, A; Jacoby, R; Juszczak, E; Lee, L; Maddison, C; Margallo-Lana, M; O'Brien, J; Sadler, S; Swann, A; Thomas, A	1
Kaufer, D; Mendiondo, MS; Quarg, P; Small, GW; Spiegel, R	1
Caffari, B; Maggini, M; Martini, N; Raschetti, R; Sorrentino, GC; Vanacore, N	1
Desai, AK; Grossberg, GT	1
Lane, R; Vincent, S	1
Grossberg, GT	1
Edgar, C; Emre, M; Lane, R; McKeith, I; Wesnes, KA	1
Jelic, V; Kivipelto, M; Winblad, B	1
Alvarez, AM; Andrade, FC; Avila, R; Bottino, CM; Bustamante, SE; Câmargo, CH; Carvalho, IA; Hototian, SR; Saffi, F; Zukauskas, PR	2
Muhlack, S; Müller, T; Przuntek, H	1
Ownby, RL	1
Aasen, I; Kumari, V; Reed, C; Sharma, T	1
Appels, BA; Beijnen, JH; De Boer, A; Frankfort, SV; Koks, CH; Tulner, LR; Van Campen, JP	1
Beck, C; Blank, K; Colenda, CC; Doraiswamy, MP; Kalunian, DA; Lyketsos, CG; Yaffe, K	1
Arciniegas, D; Chen, M; Gunay, I; Harvey, PD; Katz, DI; Koumaras, B; Mirski, D; Potkin, SG; Reyes, P; Silver, JM; Warden, D	1
Appels, BA; Beijnen, JH; de Boer, A; Frankfort, SV; Koks, CH; Schmand, BA; Tulner, LR; van Campen, JP	1
Chilovi, BV; Costardi, D; Franzoni, S; Padovani, A; Rozzini, L; Trabucchi, M	1
Agbokou, C; Ferreri, F; Gauthier, S	1
Campanozzi, MD; Casali, E; Martini, E; Neri, M; Neviani, F	1
Chouinard, S; Cohen, H; Godbout, R; Guillem, F; Melun, JP; Poulin, J; Stip, E	1
Adler, G; Gunay, I; Ibach, B; Riepe, MW; Tracik, F; Weinkauf, B	1
Hauser, WA; Noble, JM	1
Petersen, RC	1
Burns, A; Charles, HC; Cummings, J; del Ser, T; Farlow, M; Feldman, HH; Ferris, S; Fox, NC; He, Y; Herrmann, N; Inzitari, D; Lane, R; Mancione, L; Orgogozo, JM; Potkin, S; Sauer, H; Scarpini, E; Scheltens, P; Sfikas, N; Tekin, S; Winblad, B	1
Kircher, T; Leucht, S; Thienel, R; Voss, B	1
Gorelick, PB; Nyenhuis, DL	1
Faber, PL; Gianotti, LR; Kochi, K; Künig, G; Lehmann, D; Pascual-Marqui, RD; Schreiter-Gasser, U	1
Schneider, LS	2
Chen, Y; Constantini, S; Shohami, E; Weinstock, M	1
Lacomblez, L	1
Agid, Y; Anand, R; Cicin-Sain, A; Dal-Bianco, P; Gauthier, S; Gharabawi, M; Hartman, R; Rösler, M; Stähelin, HB	1
Birks, J; Iakovidou, V; Tsolaki, M	2
Byrne, EJ; Grace, JB; McKeith, IG; Perry, EK; Stevens, T; Walker, Z; Wilkinson, D	1
Luce, AK; McKeith, IG; Reading, PJ	1

Reviews

23 review(s) available for rivastigmine and Cognition Disorders

Article	Year
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Expert opinion on drug safety, 2017, Volume: 16, Issue:9 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Piperidines; Rivastigmine; Severity of Illness Index	2017
Drugs for cognitive loss and dementia. Treatment guidelines from the Medical Letter, 2013, Volume: 11, Issue:134 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Rivastigmine	2013
Rivastigmine for Alzheimer's disease. The Cochrane database of systematic reviews, 2015, Apr-10, Issue:4 Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Drug Administration Schedule; Humans; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index	2015
Pharmacotherapy for chronic cognitive impairment in traumatic brain injury. The Cochrane database of systematic reviews, 2015, Dec-01, Issue:12 Topics: Adolescent; Adult; Aged; Atomoxetine Hydrochloride; Benzhydryl Compounds; Brain Injuries; Chronic Disease; Cognition; Cognition Disorders; Humans; Middle Aged; Modafinil; Nootropic Agents; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2015
[The role of rivastigmine (exelon) in the treatment of consequences of cranial-brain trauma]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2009, Volume: 109, Issue:1 Topics: Brain Injuries; Cognition; Cognition Disorders; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Treatment Outcome	2009
Rivastigmine for Alzheimer's disease. The Cochrane database of systematic reviews, 2009, Apr-15, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index	2009
Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. The neurologist, 2009, Volume: 15, Issue:4 Topics: Acetylcholine; Administration, Oral; Aged; Brain; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Humans; Lewy Body Disease; Male; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Placebos; Rivastigmine; Treatment Outcome	2009
Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. The Annals of pharmacotherapy, 2012, Volume: 46, Issue:4 Topics: Antidepressive Agents; Cholinesterase Inhibitors; Cognition Disorders; Depression; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine	2012
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. The Cochrane database of systematic reviews, 2012, Mar-14, Issue:3 Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Lewy Body Disease; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2012
Current treatments for Alzheimer's disease: cholinesterase inhibitors. The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 9 Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Multicenter Studies as Topic; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2003
Fluctuations in cognition and alertness in Parkinson's disease and dementia. Neurology, 2004, Oct-26, Volume: 63, Issue:8 Suppl 3 Topics: Awareness; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Double-Blind Method; Humans; Lewy Body Disease; Melatonin; Multicenter Studies as Topic; Parkinson Disease; Phenylcarbamates; Phototherapy; Randomized Controlled Trials as Topic; Rivastigmine	2004
The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. The Journal of neuropsychiatry and clinical neurosciences, 2004,Fall, Volume: 16, Issue:4 Topics: Aged; Basal Ganglia Diseases; Behavior; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Cognition Disorders; Donepezil; Humans; Indans; Lewy Body Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Tacrine	2004
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. International journal of clinical practice, 2005, Volume: 59, Issue:4 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors; Treatment Outcome	2005
Rivastigmine for Alzheimer's disease. Expert review of neurotherapeutics, 2005, Volume: 5, Issue:5 Topics: Alzheimer Disease; Animals; Cognition Disorders; Dementia; Expert Testimony; Humans; Meta-Analysis as Topic; Models, Biological; Neuroprotective Agents; Phenylcarbamates; Predictive Value of Tests; Randomized Controlled Trials as Topic; Rivastigmine	2005
Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. Current medical research and opinion, 2005, Volume: 21, Issue:10 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Humans; Mental Disorders; Meta-Analysis as Topic; Neuroprotective Agents; Phenylcarbamates; Rivastigmine	2005
Clinical trials in mild cognitive impairment: lessons for the future. Journal of neurology, neurosurgery, and psychiatry, 2006, Volume: 77, Issue:4 Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Lactones; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index; Sulfones; Vitamin E	2006
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. Journal of psychiatry & neuroscience : JPN, 2006, Volume: 31, Issue:6 Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Schizophrenic Psychology; Treatment Outcome	2006
[Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview]. Der Nervenarzt, 2008, Volume: 79, Issue:1 Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Physostigmine; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2008
Diagnosis and management of vascular cognitive impairment. Current atherosclerosis reports, 2007, Volume: 9, Issue:4 Topics: Central Nervous System Agents; Clinical Trials as Topic; Cognition Disorders; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine	2007
New therapeutic approaches to Alzheimer's disease. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 14 Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon	1996
New therapeutic approaches to cognitive impairment. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 11 Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Monoamine Oxidase Inhibitors; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon	1998
Rivastigmine for Alzheimer's disease. The Cochrane database of systematic reviews, 2000, Issue:2 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbamates; Rivastigmine; Severity of Illness Index	2000
Rivastigmine for Alzheimer's disease. The Cochrane database of systematic reviews, 2000, Issue:4 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index	2000

Trials

42 trial(s) available for rivastigmine and Cognition Disorders

Article	Year
Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers. Progress in neuro-psychopharmacology & biological psychiatry, 2014, Apr-03, Volume: 50 Topics: Adolescent; Adult; Cholinesterase Inhibitors; Cocaine-Related Disorders; Cognition Disorders; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Investigational; Female; Humans; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Young Adult	2014
The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. BMC neurology, 2013, Dec-03, Volume: 13 Topics: Accidental Falls; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Male; Parkinson Disease; Phenylcarbamates; Quality of Life; Rivastigmine; Statistics, Nonparametric; Treatment Outcome	2013
Cognitive function in early clinical phase huntington disease after rivastigmine treatment. Psychiatria Danubina, 2014, Volume: 26, Issue:3 Topics: Adult; Cognition Disorders; Dementia; Double-Blind Method; Female; Humans; Huntington Disease; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychometrics; Rivastigmine; Slovenia	2014
Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease. American journal of Alzheimer's disease and other dementias, 2016, Volume: 31, Issue:3 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Rivastigmine; Severity of Illness Index; Transdermal Patch	2016
Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily). CNS neuroscience & therapeutics, 2016, Volume: 22, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Cognition Disorders; Double-Blind Method; Drug Administration Routes; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Middle Aged; Neuroprotective Agents; Retrospective Studies; Rivastigmine; Statistics, Nonparametric; Transdermal Patch; Treatment Outcome	2016
Effects of rivastigmine on memory and cognition in multiple sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2008, Volume: 35, Issue:4 Topics: Adolescent; Adult; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Humans; Memory Disorders; Middle Aged; Multiple Sclerosis; Neuroprotective Agents; Phenylcarbamates; Placebos; Psychological Tests; Rivastigmine	2008
Long-term effects of rivastigmine capsules in patients with traumatic brain injury. Brain injury, 2009, Volume: 23, Issue:2 Topics: Adult; Brain Injuries; Capsules; Cognition Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Time; Treatment Outcome	2009
A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury-what it showed and taught? Brain injury, 2009, Volume: 23, Issue:6 Topics: Adult; Brain Injury, Chronic; Cholinesterase Inhibitors; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Phenylcarbamates; Quality of Life; Rivastigmine; Treatment Outcome	2009
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenetics and genomics, 2009, Volume: 19, Issue:8 Topics: Alzheimer Disease; Biomarkers; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Progression; Female; Genotype; Humans; Male; Neuroprotective Agents; Pharmacogenetics; Phenylcarbamates; Placebos; Retrospective Studies; Rivastigmine; Treatment Outcome	2009
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. Gender medicine, 2009, Volume: 6, Issue:2 Topics: Aged; Alzheimer Disease; Cognition Disorders; Disease Progression; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Proportional Hazards Models; Rivastigmine; Sex Factors	2009
A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta neurologica Scandinavica, 2010, Volume: 121, Issue:4 Topics: Aged; Aged, 80 and over; Brain Ischemia; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Double-Blind Method; Executive Function; Female; Humans; Male; Middle Aged; Phenylcarbamates; Pilot Projects; Rivastigmine; Stroke; Treatment Outcome	2010
Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2010, Volume: 6, Issue:1 Topics: Aged; Behavioral Symptoms; Cognition Disorders; Dementia; Female; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Supranuclear Palsy, Progressive	2010
The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Multiple sclerosis (Houndmills, Basingstoke, England), 2011, Volume: 17, Issue:11 Topics: Adult; Attention; Brain; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Double-Blind Method; Female; Finland; Humans; Magnetic Resonance Imaging; Memory; Middle Aged; Multiple Sclerosis; Neuropsychological Tests; Phenylcarbamates; Placebos; Reaction Time; Rivastigmine; Time Factors; Treatment Outcome	2011
Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:5 Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Mental Recall; Middle Aged; Multiple Sclerosis; Phenylcarbamates; Rivastigmine; Treatment Outcome	2013
[Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease]. Revue neurologique, 2002, Volume: 158, Issue:8-9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Tolerance; Female; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index	2002
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:6 Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Electroencephalography; Event-Related Potentials, P300; Female; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Prospective Studies; Reaction Time; Rivastigmine; Tacrine; Treatment Outcome	2003
Prediction of treatment response to rivastigmine in Alzheimer's dementia. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Administration Schedule; Electroencephalography; Female; Humans; Male; Memory, Short-Term; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Theta Rhythm	2004
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. European journal of neurology, 2004, Volume: 11, Issue:4 Topics: Aged; Alzheimer Disease; Apolipoproteins E; Attention; Carbamates; Case-Control Studies; Chi-Square Distribution; Cholinesterases; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Statistics as Topic; Time Factors	2004
Behavioral symptoms in mild cognitive impairment. Neurology, 2004, Apr-13, Volume: 62, Issue:7 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine	2004
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. International journal of clinical practice, 2004, Volume: 58, Issue:4 Topics: Aged; Aged, 80 and over; Aspirin; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Drug Therapy, Combination; Female; Humans; Male; Nimodipine; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Treatment Outcome; Vasodilator Agents	2004
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. Archives of gerontology and geriatrics. Supplement, 2004, Issue:9 Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index	2004
Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12 Topics: Adult; Aged; Cognition Disorders; Demography; Female; Humans; Huntington Disease; Male; Middle Aged; Movement Disorders; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Trinucleotide Repeat Expansion	2004
Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Current medical research and opinion, 2004, Volume: 20, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Status Schedule; Neuroprotective Agents; Neuropsychological Tests; Nursing Homes; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome	2004
Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:1 Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Injuries; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Performance; Rivastigmine; Treatment Outcome	2005
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology, 2004, Dec-28, Volume: 63, Issue:12 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Donepezil; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Patient Satisfaction; Patients; Phenylcarbamates; Physical Therapy Modalities; Piperidines; Psychomotor Disorders; Rivastigmine; Single-Blind Method; Treatment Outcome	2004
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ (Clinical research ed.), 2005, Apr-16, Volume: 330, Issue:7496 Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Dibenzothiazepines; Double-Blind Method; Humans; Middle Aged; Phenylcarbamates; Psychomotor Agitation; Quetiapine Fumarate; Rivastigmine; Treatment Failure	2005
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. European journal of clinical pharmacology, 2005, Volume: 61, Issue:5-6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Italy; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome	2005
Rivastigmine in vascular dementia. International psychogeriatrics, 2003, Volume: 15 Suppl 1 Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Double-Blind Method; Drug Administration Schedule; Humans; Neuropsychological Tests; Phenylcarbamates; Pilot Projects; Rivastigmine; Severity of Illness Index	2003
Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology, 2005, Nov-22, Volume: 65, Issue:10 Topics: Aged; Aged, 80 and over; Attention; Cognition; Cognition Disorders; Corpus Striatum; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Frontal Lobe; Humans; Male; Middle Aged; Neural Pathways; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Placebos; Reaction Time; Rivastigmine; Treatment Outcome	2005
Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study. Clinical rehabilitation, 2005, Volume: 19, Issue:8 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Anxiety; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Cognitive Behavioral Therapy; Depression; Female; Humans; Male; Mental Status Schedule; Middle Aged; Phenylcarbamates; Pilot Projects; Rivastigmine; Treatment Outcome	2005
Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease. Pharmacopsychiatry, 2006, Volume: 39, Issue:1 Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cognition Disorders; Female; Humans; Male; Middle Aged; Movement; Neuroprotective Agents; Phenylcarbamates; Psychomotor Performance; Reaction Time; Rivastigmine	2006
Quetiapine and rivastigmine for agitation in Alzheimer's disease. Current psychiatry reports, 2006, Volume: 8, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dibenzothiazepines; Disease Progression; Double-Blind Method; Humans; Phenylcarbamates; Psychomotor Agitation; Quetiapine Fumarate; Rivastigmine	2006
Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophrenia research, 2006, Volume: 85, Issue:1-3 Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Ganglionic Stimulants; Humans; Male; Middle Aged; Neuropsychological Tests; Nicotine; Phenylcarbamates; Physostigmine; Psychomotor Performance; Rivastigmine; Schizophrenia; Severity of Illness Index; Verbal Behavior	2006
Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology, 2006, Sep-12, Volume: 67, Issue:5 Topics: Adolescent; Adult; Antiemetics; Benzamides; Brain Injuries; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Rivastigmine; Treatment Outcome; Vomiting	2006
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Rivastigmine; Time Factors; Treatment Outcome	2007
Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. International journal of geriatric psychiatry, 2007, Volume: 22, Issue:4 Topics: Activities of Daily Living; Aged; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality Therapy; Computer-Assisted Instruction; Donepezil; Female; Galantamine; Humans; Indans; Intelligence; Longitudinal Studies; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Nootropic Agents; Orientation; Phenylcarbamates; Piperidines; Problem Solving; Retrospective Studies; Rivastigmine; Software; Treatment Outcome	2007
Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Current medical research and opinion, 2007, Volume: 23, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Probability; Reference Values; Risk Assessment; Rivastigmine; Schizophrenia; Severity of Illness Index; Treatment Outcome	2007
Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. Dementia and geriatric cognitive disorders, 2007, Volume: 23, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Memory; Phenylcarbamates; Pilot Projects; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Outcome	2007
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. The Lancet. Neurology, 2007, Volume: 6, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Tremor; Vomiting	2007
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (Clinical research ed.), 1999, Mar-06, Volume: 318, Issue:7184 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine	1999
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. International journal of geriatric psychiatry, 2000, Volume: 15, Issue:5 Topics: Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Tolerance; Female; Humans; Lewy Body Disease; Male; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Treatment Outcome	2000
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:6 Topics: Aged; Carbamates; Caregivers; Cognition Disorders; Female; Follow-Up Studies; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Stress, Psychological; Treatment Outcome	2001

Other Studies

34 other study(ies) available for rivastigmine and Cognition Disorders

Article	Year
Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Annals of neurology, 2021, Volume: 89, Issue:1 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Hypotension; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Rivastigmine	2021
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. Medicina, 2013, Volume: 73, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Child; Child, Preschool; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Dementia, Vascular; Donepezil; Drug Prescriptions; Female; Galantamine; Humans; Indans; Infant; Male; Memantine; Middle Aged; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Young Adult	2013
Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia. Metabolic brain disease, 2013, Volume: 28, Issue:3 Topics: Acetylcholinesterase; Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Brain; Cholinesterase Inhibitors; Cognition Disorders; Electroshock; Excitatory Amino Acid Antagonists; Ketamine; Male; Memory; Memory, Short-Term; Motor Activity; Neuroprotective Agents; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Schizophrenia; Schizophrenic Psychology	2013
Reduced N-acetylaspartate to creatine ratio in the posterior cingulate correlates with cognition in Alzheimer's disease following four months of rivastigmine treatment. Dementia and geriatric cognitive disorders, 2015, Volume: 39, Issue:1-2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cholinesterase Inhibitors; Cognition Disorders; Creatine; Female; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Phenylcarbamates; Rivastigmine	2015
Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats. Naunyn-Schmiedeberg's archives of pharmacology, 2016, Volume: 389, Issue:10 Topics: Animals; Behavior, Animal; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Ethanol; Indans; Male; Maze Learning; Memory Disorders; Motor Activity; Nootropic Agents; Piperidines; Rats, Wistar; Reaction Time; Rivastigmine; Rotarod Performance Test; Spatial Memory; Time Factors	2016
Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. Journal of neuroimmunology, 2008, Oct-15, Volume: 203, Issue:1 Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antigen Presentation; Cell Division; Cholinesterase Inhibitors; Cognition Disorders; Cytokines; Demyelinating Diseases; Encephalomyelitis, Autoimmune, Experimental; Female; Immunosuppressive Agents; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Phenylcarbamates; Receptors, Nicotinic; Rivastigmine; Space Perception; T-Lymphocytes	2008
Brain cholinergic impairment in liver failure. Brain : a journal of neurology, 2008, Volume: 131, Issue:Pt 11 Topics: Acetylcholine; Acetylcholinesterase; Aged; Aged, 80 and over; Animals; Behavior, Animal; Cerebral Cortex; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis, Experimental; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; RNA, Messenger	2008
Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology, 2009, Volume: 202, Issue:1-3 Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Maze Learning; Memory; Methylene Blue; Mice; Muscarinic Antagonists; Nootropic Agents; Phenylcarbamates; Postural Balance; Rivastigmine; Scopolamine; Space Perception; Swimming	2009
BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Movement disorders : official journal of the Movement Disorder Society, 2009, Feb-15, Volume: 24, Issue:3 Topics: Aged; Apolipoprotein E4; Butyrylcholinesterase; Cognition Disorders; Female; Gene Frequency; Genotype; Humans; Hyperhomocysteinemia; Lewy Body Disease; Male; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychomotor Disorders; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index	2009
[Progressive supranucleair palsy: acetylcholineeserase-inhibitor a possible therapy?]. Tijdschrift voor gerontologie en geriatrie, 2009, Volume: 40, Issue:3 Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Deglutition Disorders; Diagnosis, Differential; Fatal Outcome; Female; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Supranuclear Palsy, Progressive; Treatment Outcome	2009
Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine. Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:12 Topics: Animals; Avoidance Learning; Cholinergic Antagonists; Cognition; Cognition Disorders; Drug Therapy, Combination; Intestines; Male; Mice; Mice, Inbred Strains; Muscle Cramp; Neuroprotective Agents; Peripheral Nervous System Diseases; Phenylcarbamates; Random Allocation; Rivastigmine; Salivation; Scopolamine; Solanaceous Alkaloids	2009
Neurometabolic correlations of donepezil and rivastigmine in dementia patients: a different neuroprotective effect. The Journal of neuropsychiatry and clinical neurosciences, 2009,Summer, Volume: 21, Issue:3 Topics: Aged; Aspartic Acid; Brain; Cognition Disorders; Dementia; Donepezil; Female; Humans; Indans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine; Treatment Outcome	2009
Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study. Journal of clinical pharmacy and therapeutics, 2009, Volume: 34, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Pilot Projects; Rivastigmine; Subarachnoid Hemorrhage	2009
Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. American journal of Alzheimer's disease and other dementias, 2010, Volume: 25, Issue:5 Topics: Cognition; Cognition Disorders; Dementia; Humans; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome	2010
Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire. The journal of nutrition, health & aging, 2011, Volume: 15, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Disease Progression; Educational Status; Female; Geriatric Assessment; Humans; Institutionalization; Logistic Models; Male; Memantine; Middle Aged; Observation; Phenylcarbamates; Qualitative Research; Risk Factors; Rivastigmine; Surveys and Questionnaires	2011
Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. Behavioural brain research, 2011, Nov-20, Volume: 225, Issue:1 Topics: Amyloid beta-Peptides; Analysis of Variance; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Indans; Male; Mice; Mice, Inbred ICR; Motor Activity; Peptide Fragments; Phenylcarbamates; Piperidines; Recognition, Psychology; Rivastigmine	2011
Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. American journal of Alzheimer's disease and other dementias, 2011, Volume: 26, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Databases, Factual; Humans; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Retrospective Studies; Rivastigmine; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome	2011
Protective role of curcumin on colchicine-induced cognitive dysfunction and oxidative stress in rats. Human & experimental toxicology, 2012, Volume: 31, Issue:7 Topics: Acetylcholinesterase; Animals; Antioxidants; Brain; Catalase; Cholinesterase Inhibitors; Cognition Disorders; Colchicine; Curcumin; Glutathione; Lipid Peroxidation; Male; Malondialdehyde; Memory; Neuroprotective Agents; Oxidative Stress; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine	2012
Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients. Journal of Alzheimer's disease : JAD, 2012, Volume: 31, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Phenethylamines; Phenols; Phenylcarbamates; Pilot Projects; Rivastigmine; Taiwan	2012
Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke, 2004, Volume: 35, Issue:4 Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Controlled Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine; Stroke; Terminology as Topic	2004
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. Journal of neurochemistry, 2004, Volume: 88, Issue:5 Topics: Acetylcholinesterase; Aged; Alternative Splicing; Alzheimer Disease; Blotting, Western; Carbamates; Centrifugation, Density Gradient; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Isoenzymes; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parietal Lobe; Phenylcarbamates; Rivastigmine; Tacrine; Time	2004
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of child neurology, 2004, Volume: 19, Issue:3 Topics: Acetylcholine; Autistic Disorder; Brain; Carbamates; Child; Child Development Disorders, Pervasive; Child, Preschool; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Language Development Disorders; Male; Neuropsychological Tests; Pattern Recognition, Visual; Personality Assessment; Phenylcarbamates; Rivastigmine; Social Behavior; Treatment Outcome; Vocabulary	2004
A case study in the treatment of dementia with Lewy bodies. Acta psychiatrica Scandinavica, 2004, Volume: 110, Issue:1 Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galantamine; Hallucinations; Humans; Indans; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Agitation; Rivastigmine; Social Behavior	2004
Impact of APOE in mild cognitive impairment. Neurology, 2004, Nov-23, Volume: 63, Issue:10 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Atrophy; Cognition Disorders; Female; Genetic Predisposition to Disease; Genotype; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine	2004
Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. International journal of clinical practice, 2006, Volume: 60, Issue:6 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Female; Humans; Male; Memory Disorders; Middle Aged; Phenylcarbamates; Retrospective Studies; Rivastigmine; Treatment Outcome	2006
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:7 Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Geriatric Psychiatry; Health Services for the Aged; Humans; Phenylcarbamates; Professional-Family Relations; Rivastigmine; Sesquiterpenes; Tacrine; United States	2006
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl). Archives of gerontology and geriatrics, 2007, Volume: 44 Suppl 1 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability Evaluation; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Mental Disorders; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index	2007
Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology, 2007, May-15, Volume: 68, Issue:20 Topics: Brain Injuries; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Humans; Memory Disorders; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Research Design; Rivastigmine; Treatment Outcome	2007
MCI treatment trials: failure or not? The Lancet. Neurology, 2007, Volume: 6, Issue:6 Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Humans; Phenylcarbamates; Rivastigmine; Treatment Failure	2007
Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease. Psychopharmacology, 2008, Volume: 198, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; Electroencephalography; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Psychomotor Performance; Rivastigmine	2008
Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. Journal of neurotrauma, 1998, Volume: 15, Issue:4 Topics: Animals; Brain Edema; Carbamates; Cholinergic Antagonists; Cholinesterase Inhibitors; Cognition Disorders; Head Injuries, Closed; Male; Maze Learning; Mecamylamine; Memory; Mice; Movement; Movement Disorders; Muscarinic Antagonists; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Scopolamine	1998
[Drug therapy strategies in Alzheimer's disease]. La Revue du praticien, 1998, Nov-01, Volume: 48, Issue:17 Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Depression; Donepezil; Humans; Indans; Mental Disorders; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Sleep Wake Disorders; Tacrine	1998
Alzheimer's disease: translating neurochemical insights into clinical benefits. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:10 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Magnetic Resonance Imaging; Phenylcarbamates; Rivastigmine; Treatment Outcome; Trichlorfon	2000
[Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report]. Arquivos de neuro-psiquiatria, 2002, Volume: 60, Issue:1 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Patient Care Team; Phenylcarbamates; Rivastigmine	2002